Bioequivalence Evaluation in Healthy Volunteers: New Generic Formulations of Sitagliptin and Sitagliptin–Metformin Fixed-Dose Combination Compared with the Originator Products

INTRODUCTION: Three studies compared the bioequivalence (BE) of new generic tablet formulations of sitagliptin (100 mg; fasting) and the fixed-dose combination (FDC) of sitagliptin/metformin (50/850 mg, 50/1000 mg; both fed) in healthy volunteers with the same tablet strengths of the reference produ...

Descripción completa

Detalles Bibliográficos
Autores principales: Schnaars, Yvonne, Gaikwad, Sumedh, Gottwald-Hostalek, Ulrike, Uhl, Wolfgang, Ribot, Olga, Varanasi, Kanthikiran V. S., Rodríguez, Laura, Torrejón, Javier, Gómez, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943811/
https://www.ncbi.nlm.nih.gov/pubmed/36526947
http://dx.doi.org/10.1007/s13300-022-01349-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9943811/
https://www.ncbi.nlm.nih.gov/pubmed/36526947
http://dx.doi.org/10.1007/s13300-022-01349-2

Ejemplares similares